Literature DB >> 25075166

Predictors and prognostic implications of major adverse cardiovascular events after renal transplant: 10 years outcomes in 321 patients.

Waqas Aftab1, Padmini Varadarajan1, Shuja Rasool1, Ramdas G Pai1.   

Abstract

Renal transplantation is the treatment of choice in patients with end-stage renal disease. Major adverse cardiac events (MACE) are common after renal transplant, especially in the perioperative period, leading to excess morbidity and mortality. The predictors and long-term prognostic implications of MACE are poorly understood. We analyzed predictors and implications of MACE in a cohort of 321 consecutive adult patients, who received renal allograft transplantation between 1995 and 2003 at our institution. The characteristics of 321 patients were: age at transplant 44 ± 13 years, 60% male, 36% diabetes mellitus (DM), left ventricular ejection fraction (LVEF) 60 ± 16%. MACE occurred in 21 patients with cumulative rate of 6.5% over 3 years after renal transplant, 57% occurring within 30 days, 67% within 90 days, and 86% within 180 days. MACE was not predicted by any clinical or pharmacological variables including age, gender, hypertension, DM, prior myocardial infarction, smoking, duration of dialysis, LVEF, or therapy with β-blockers (BB), angiotensin converting enzyme inhibitors, or calcium channel blockers. However, a clinical decision to perform a stress test or a coronary angiogram was predictive of higher MACE rate. MACE, irrespective of type, was independently associated with higher mortality over a period up to 15 years and this seemed to be blunted by BB therapy. MACE rate after renal transplantation decreases over time, most occurring in the first 90 days and is not predicted by any of the traditional risk factors or drug therapies. It is associated with higher long-term mortality.

Entities:  

Keywords:  end-stage renal disease; major adverse cardiac events; survival

Year:  2014        PMID: 25075166      PMCID: PMC4082448          DOI: 10.1055/s-0034-1372248

Source DB:  PubMed          Journal:  Int J Angiol        ISSN: 1061-1711


  21 in total

1.  Incidence and predictors of myocardial infarction after kidney transplantation.

Authors:  Krista L Lentine; Daniel C Brennan; Mark A Schnitzler
Journal:  J Am Soc Nephrol       Date:  2004-12-22       Impact factor: 10.121

2.  Universal definition of myocardial infarction.

Authors:  Kristian Thygesen; Joseph S Alpert; Harvey D White
Journal:  J Am Coll Cardiol       Date:  2007-11-27       Impact factor: 24.094

3.  Long-term survival in renal transplant recipients with graft function.

Authors:  A O Ojo; J A Hanson; R A Wolfe; A B Leichtman; L Y Agodoa; F K Port
Journal:  Kidney Int       Date:  2000-01       Impact factor: 10.612

4.  Diabetes mellitus after renal transplantation: as deleterious as non-transplant-associated diabetes?

Authors:  A M Miles; N Sumrani; R Horowitz; P Homel; V Maursky; M S Markell; D A Distant; J H Hong; B G Sommer; E A Friedman
Journal:  Transplantation       Date:  1998-02-15       Impact factor: 4.939

5.  Markers of inflammation before and after renal transplantation.

Authors:  Alfonso M Cueto-Manzano; Luis E Morales-Buenrostro; Liliana González-Espinoza; Norma González-Tableros; Fabiola Martín-del-Campo; Ricardo Correa-Rotter; Isela Valera; Josefina Alberú
Journal:  Transplantation       Date:  2005-07-15       Impact factor: 4.939

6.  Myocardial microvascular disease and major adverse cardiovascular events in patients with end-stage renal disease: rationale and design of the MICROCARD study.

Authors:  Theodora Bejan-Angoulvant; Cyrille Bergerot; Laurent Juillard; Aline Mezergues; Emmanuel Morelon; Claire Pouteil-Noble; Xavier André-Fouët; Denis Angoulvant
Journal:  Nephrol Dial Transplant       Date:  2012-02-17       Impact factor: 5.992

Review 7.  Cardiovascular disease in end stage renal disease.

Authors:  R Sharma; D Pellerin; S J D Brecker
Journal:  Minerva Urol Nefrol       Date:  2006-06       Impact factor: 3.720

8.  Coronary angiography is the best predictor of events in renal transplant candidates compared with noninvasive testing.

Authors:  Jose Jayme G De Lima; Emil Sabbaga; Marcelo Luis C Vieira; Flavio J de Paula; Luis E Ianhez; Eduardo M Krieger; Jose Antonio F Ramires
Journal:  Hypertension       Date:  2003-08-11       Impact factor: 10.190

9.  Reactive glycosylation endproducts in diabetic uraemia and treatment of renal failure.

Authors:  Z Makita; R Bucala; E J Rayfield; E A Friedman; A M Kaufman; S M Korbet; R H Barth; J A Winston; H Fuh; K R Manogue
Journal:  Lancet       Date:  1994-06-18       Impact factor: 79.321

10.  Fluvastatin and perioperative events in patients undergoing vascular surgery.

Authors:  Olaf Schouten; Eric Boersma; Sanne E Hoeks; Robbert Benner; Hero van Urk; Marc R H M van Sambeek; Hence J M Verhagen; Nisar A Khan; Martin Dunkelgrun; Jeroen J Bax; Don Poldermans
Journal:  N Engl J Med       Date:  2009-09-03       Impact factor: 91.245

View more
  2 in total

Review 1.  Cardiovascular risk factors following renal transplant.

Authors:  Jill Neale; Alice C Smith
Journal:  World J Transplant       Date:  2015-12-24

Review 2.  Diabetes and Cardiovascular Risk in Renal Transplant Patients.

Authors:  Jacek Rysz; Beata Franczyk; Maciej Radek; Aleksandra Ciałkowska-Rysz; Anna Gluba-Brzózka
Journal:  Int J Mol Sci       Date:  2021-03-26       Impact factor: 5.923

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.